ReviewWorld journal of gastrointestinal pharmacology and therapeutics2018
Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?
Review in World journal of gastrointestinal pharmacology and therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07707011 (Potassium Competitive Acid Blocker), which is not on this map. Cited by 40 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Potassium Competitive Acid Blocker (PCAB) Test-Guided vs Physiologic Test-Guided Treatment in Patients With Typical Reflux Symptoms: A Randomized Non-inferiority Trial
Who cites it
40 citing papers in PubMed, 4 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Proton pump inhibitors for prevention of upper and lower gastrointestinal bleeding in patients taking aspirin: a systematic review and meta-analysis.European journal of clinical pharmacology · 2026Pooled it
- Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for patients withFrontiers in microbiology · 2025Pooled it
- Efficacy and safety of vonoprazan versus proton pump inhibitors in the treatment of peptic ulcer disease: a systematic review and network meta-analysis for randomized controlled trails.Frontiers in nutrition · 2024Pooled it
- A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis.Journal of gastroenterology and hepatology · 2022Pooled it
- Randomized, Double-Blind, Active-Controlled, Parallel, Phase 3 Clinical Trial for Evaluating the Efficacy and Safety of Zastaprazan in Patients with Gastric Ulcers.Gut and liver · 2026Trial
- The pharmacokinetics and safety of vonoprazan in adolescents and children with gastroesophageal reflux disease.Journal of pediatric gastroenterology and nutrition · 2026Trial
- Keverprazan, a novel potassium-competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects.Clinical and translational science · 2023Trial
- Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis.Alimentary pharmacology & therapeutics · 2023Trial
- Potassium-Competitive Acid Blockers as a New Frontier in Acid-Related Disorders and the Role of South Korean Pharmacological Innovation.Pharmaceuticals (Basel, Switzerland) · 2026Review
- CYP3A-Mediated Metabolism of Zastaprazan in Humans and Associated Drug-Drug Interactions.Pharmaceutics · 2026Article
- Risk of Depression Related to Use of Proton Pump Inhibitors and Tegoprazan: A Nationwide Cohort Study.Journal of Korean medical science · 2026Article
- Potassium-Competitive Acid Blockers for First-LineGastro hep advances · 2026Review
- Vonoprazan as an adjuvant to cisplatin: enhancing antitumor efficacy while mitigating nephrotoxicity and gastrointestinal adverse effects.Frontiers in pharmacology · 2026Article
- Observational
- Optimizing acid-related disease management: insights into potassium-competitive acid blockers and proton pump inhibitors.European journal of clinical pharmacology · 2025Review
- Effect of Potassium-Competitive Acid Blockers on Upper Gastrointestinal Bleeding in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Nationwide Cohort Study.Journal of gastroenterology and hepatology · 2025Article
- Review
- Review
- Efficacy of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors for Gastric Ulcers: Bayesian and Frequentist Network Meta-Analysis With Cross-Inference Through a Quality management System.Current therapeutic research, clinical and experimental · 2025Article
- Potassium-competitive acid blockers and advances in the management of patients with acid-related diseases: a narrative review.Frontiers in physiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The modern lifestyle caters to an increase in the incidence of peptic ulcer disease, gastroesophageal reflux disease and several other acid-related conditions of the gut. The drugs to prevent these conditions work either through H2 receptor blockade or inhibition of the H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.